151751-Najiba-Chargi

332 CHAPTER 17 Appendix 4. Trismus outcomes at t0, t1 and t2 stratified by treatment modality. RT CRT (cetuximab) CRT (cisplatin) t 0 n = 42 t 1 n = 39 t 2 n = 28 t 0 n = 17 t 1 n = 17 t 2 n = 11 t 0 n = 49 t 1 n = 43 t 2 n = 32 Observer-rated outcomes Mouth opening in mmMedian (range) 49 (25-65) 47 (31-63) 48 (27-64) 48 (30-60) 42 (27-55) 43 (32-50) 47 (18-64) 40 (16-59) 41 (10-58) Trismus No 39 (93) 29 (91) 24 (86) 16 (94) 12 (75) 9 (90) 43 (96) 27 (68) 22 (71) Yes 3 (7) 3 (9) 4 (14) 1 (6) 4 (25) 1 (10) 2 (4) 13 (33) 9 (29) Unknown 0 7 0 0 1 1 4 3 1 Patient-rated outcomes Perceived trismus No 34 (100) 26 (90) 25 (93) 16 (94) 13 (81) 8 (100) 37 (93) 28 (76) 23 (82) Yes 0 (0) 3 (10) 2 (7) 1 (6) 3 (19) 0 (0) 3 (8) 9 (24) 5 (18) Unknown 8 10 1 0 1 3 9 6 4 NB: Not all percentages sum up exactly to 100% due to rounding. Abbreviations: FOIS = functional oral intake scale, NGT = nasogastric tube, PRG = percutaneous radiological gastrostomy, t0 = pretreatment, t1 = six months after treatment, t2 = twelve months after treatment